<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189995</url>
  </required_header>
  <id_info>
    <org_study_id>BMHC-4000</org_study_id>
    <nct_id>NCT00189995</nct_id>
  </id_info>
  <brief_title>Clozapine IM and Aggression in Schizophrenic Patients</brief_title>
  <official_title>Intramuscular Clozapine in the Management of Aggression in Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beersheva Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beersheva Mental Health Center</source>
  <brief_summary>
    <textblock>
      Aggressive, persistent aggression and impulsive behavior are frequently observed in&#xD;
      schizophrenic patients. According to some researchers &quot;more than 50% of all psychiatric&#xD;
      patients and 10% of schizophrenic patients show aggressive symptoms varying from threatening&#xD;
      behavior and agitation to assault&quot;(1). It is a common cause of psychiatric admission and is a&#xD;
      therapeutic issue. The treatment of these symptoms is a clinical problem for both patients&#xD;
      and staff. Violent behavior, a major detrimental factor in stigmatization of the mentally&#xD;
      ill, also poses physical danger for the patients themselves. Current pharmacotherapy of&#xD;
      pathologic aggression involves the use of multiple agents (typical and atypical&#xD;
      antipsychotics, benzodiazepines, mood stabilizers, beta-blockers, antiandrogenic hormones,&#xD;
      and selective serotonin reuptake inhibitors) on empiric basis, with varying degrees of&#xD;
      response (2-6). Unfortunately, these approaches lead to numerous side effects. Poor or&#xD;
      noncompliance with pharmacotherapy makes it difficult to choose the appropriate preparation.&#xD;
      Currently, typical neuroleptics are still the first choice in treating acute aggressive&#xD;
      symptoms, while risperidone and olanzapine could be alternatives (5-7). Typical depot&#xD;
      neuroleptics should be considered in cases where medication compliance is a problem. Most&#xD;
      clinical information on treating of aggression has been collected about atypical&#xD;
      neuroleptics, particularly regarding clozapine.&#xD;
&#xD;
      Clozapine is indicated in psychotic state and/or in drug-resistant schizophrenic patients.&#xD;
      According to the FDA - it is the drug of choice in suicidal and aggressive patients, due-to&#xD;
      psychotic state. It was found helpful in nearly 30% of resistant schizophrenic patients.&#xD;
      Concerning the parenteral administration of clozapine - very little data is available today.&#xD;
&#xD;
      This study aims to investigate efficacy and safety (psychopathology, and side effects) of&#xD;
      parenteral clozapine in treatment of aggressive behavior in schizophrenic patients in a&#xD;
      double-blind trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overt Aggression Scale</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clozapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  schizophrenic, schizoaffective, or schizophreniform according to DSM-IV&#xD;
&#xD;
          -  treatment-resistant&#xD;
&#xD;
          -  presenting pathologic violent-aggressive behavior on admission&#xD;
&#xD;
          -  at risk for self damage&#xD;
&#xD;
          -  age: 18-65&#xD;
&#xD;
          -  patient is not participating in any other study at time of this study&#xD;
&#xD;
          -  minimal score of 70 on PANSS&#xD;
&#xD;
          -  prior resistance to at least 2 different classes of neuroleptics&#xD;
&#xD;
          -  OAS scores of at least 4 points in physical aggression sections and at least 2 points&#xD;
             in verbal aggression section&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  neutropenia or any other abnormal CBC result&#xD;
&#xD;
          -  myeloproliferative disease&#xD;
&#xD;
          -  chronic physical diseases such as liver, renal or cardiac diseases&#xD;
&#xD;
          -  history of alcohol or drug abuse&#xD;
&#xD;
          -  history of drug induced granulocytopenia/agranulocytosis&#xD;
&#xD;
          -  alcoholic/drug psychosis or intoxication&#xD;
&#xD;
          -  carbamazepine or other bone marrow suppressor treatment&#xD;
&#xD;
          -  uncontrolled epilepsy&#xD;
&#xD;
          -  paralytic ileus&#xD;
&#xD;
          -  hypersensitivity to clozapine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valdimir Lerner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben-Gurion University of the Negev</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baruch Spivak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chanoch Midownik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben-Gurion University of the Negev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beersheva Mental Health Center</name>
      <address>
        <city>Beersheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nes Ziona Medical Center</name>
      <address>
        <city>Nes Ziona</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beersheva Mental Health Center</investigator_affiliation>
    <investigator_full_name>Vladimir Lerner</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>aggression</keyword>
  <keyword>clozapine</keyword>
  <keyword>efficacy</keyword>
  <keyword>double-blind</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

